Storia in 1 fonti

Alnylam's stock is down 30% despite a booming biotech market. Here's why.

Alnylam's stock is down 30% in 2026 despite Amvuttra's success. Wainua's Phase 3 failure raised doubts about RNAi silencers like Amvuttra and nucresiran. Q2 earnings due July 30.

Raccontata da

endpoints.news

Timeline cronologica

martedì 28 luglio 2026·endpoints.news
Alnylam's stock is down 30% despite a booming biotech market. Here's why.
Alnylam's stock is down 30% in 2026 despite Amvuttra's success. Wainua's Phase 3 failure raised doubts about RNAi silencers like Amvuttra and nucresiran. Q2 earnings due July 30.